Noom will submit an official statement to the congressional record at Tuesday’s Senate hearing with three specific recommendations calling for more affordable GLP-1 medications to help end the obesity epidemic. Noom launches a new petition requesting policymakers not to allow the only affordable GLP-1s to be forced off the market without fair brand-name pricing. Noom encourages the Committee to focus on two key matters in a full-page advertisement in the print edition of The Wall Street Journal.
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Noom , the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today issued a call for public support of a new petition demanding affordable choices and fair pricing for GLP-1 weight-loss medications. The petition comes ahead of a landmark hearing in which a major pharmaceutical executive will testify before the Senate Committee on Health, Education, Labor and Pensions (HELP), amidst criticisms of the company’s pricing practices for their blockbuster GLP-1 medications.
Senator Bernie Sanders (I-Vt.), Chair of the HELP Committee, has been vocal in holding pharmaceutical companies accountable to ensure fair pricing for these life-saving medications. “If Wegovy and Zepbound are removed from the shortage list, it’s the equivalent of a price hike for every American today accessing affordable weight-loss medication via 503B FDA-regulated 1 outsourcing facilities,” said .
